Stefan Wagner Selected Research

HMW-MAA

5/2011	Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity.
12/2008	Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine.
4/2005	Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody.
4/2005	Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity.
1/2005	Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefan Wagner Research Topics

Disease

28	Heart Failure 12/2021 - 03/2002
28	Neoplasms (Cancer) 01/2021 - 12/2003
9	Sleep Apnea Syndromes (Sleep Apnea) 02/2022 - 01/2018
8	Atherosclerosis 10/2018 - 02/2004
8	Melanoma (Melanoma, Malignant) 05/2011 - 10/2002
7	Atrial Fibrillation 12/2021 - 05/2010
6	Inflammation (Inflammations) 01/2020 - 02/2004
5	Glioma (Gliomas) 01/2022 - 01/2013
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 03/2008
5	Heart Diseases (Heart Disease) 01/2020 - 03/2006
4	Apnea 12/2021 - 01/2020
4	Hypertrophy 01/2021 - 08/2013
4	Infections 01/2021 - 12/2004
4	Multiple Sclerosis 10/2020 - 10/2014
4	Hypoxia (Hypoxemia) 01/2020 - 01/2013
4	Arthritis (Polyarthritis) 10/2018 - 05/2010
4	Latex Hypersensitivity (Latex Allergy) 06/2013 - 01/2005
4	Neoplasm Metastasis (Metastasis) 02/2011 - 02/2004
3	Cardiac Arrhythmias (Arrythmia) 01/2020 - 10/2014
3	Infarction (Infarctions) 01/2020 - 03/2002
3	Stroke (Strokes) 11/2015 - 05/2010
3	Hypersensitivity (Allergy) 06/2013 - 01/2007
3	Breast Neoplasms (Breast Cancer) 05/2011 - 12/2003
2	Myocardial Infarction 10/2021 - 03/2002
2	COVID-19 01/2021 - 01/2021
2	Prostatic Neoplasms (Prostate Cancer) 07/2020 - 11/2018
2	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 05/2020 - 01/2016
2	Muscular Dystrophies (Muscular Dystrophy) 01/2020 - 01/2017
2	Neuroinflammatory Diseases 01/2019 - 10/2018
2	Thinness 01/2018 - 11/2016
2	Glioblastoma (Glioblastoma Multiforme) 08/2016 - 01/2013
2	Pathologic Processes 07/2015 - 11/2007
2	Carcinogenesis 07/2015 - 05/2008
2	Epilepsy (Aura) 01/2011 - 11/2009
2	Seasonal Allergic Rhinitis (Hay Fever) 05/2009 - 01/2008

Drug/Important Bio-Agent (IBA)

16	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 02/2022 - 02/2006
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2004
13	Matrix Metalloproteinases (MMPs)IBA 01/2020 - 02/2004
6	N,N- diethyl- 2- (2- (4- (2- fluoroethoxy)phenyl)- 5,7- dimethylpyrazolo(1,5- a)pyrimidin- 3- yl)acetamideIBA 01/2021 - 11/2015
6	Calcium-Calmodulin-Dependent Protein KinasesIBA 10/2020 - 12/2006
6	VaccinesIBA 05/2011 - 07/2004
6	Peptides (Polypeptides)IBA 05/2011 - 10/2002
5	Pharmaceutical PreparationsIBA 01/2022 - 11/2007
5	Glucose (Dextrose)FDA LinkGeneric 07/2021 - 01/2013
5	SodiumIBA 07/2021 - 08/2013
5	Biological ProductsIBA 01/2020 - 07/2004
5	Immunoglobulin E (IgE)IBA 06/2013 - 01/2007
5	HMW-MAAIBA 05/2011 - 01/2005
4	Amino Acids FDA Link 01/2022 - 01/2013
4	AntigensIBA 01/2020 - 12/2003
4	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2019 - 11/2003
4	EpitopesIBA 05/2011 - 10/2002
4	Monoclonal AntibodiesIBA 11/2007 - 10/2002
3	Messenger RNA (mRNA)IBA 01/2021 - 01/2020
3	RNA (Ribonucleic Acid)IBA 01/2021 - 11/2019
3	Ion Channels (Ion Channel)IBA 01/2021 - 06/2009
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2016
3	CalciumIBA 01/2020 - 07/2006
3	Ranolazine FDA Link 01/2016 - 05/2010
3	AntibodiesIBA 05/2011 - 12/2003
3	Endothelins (Endothelin)IBA 02/2011 - 03/2006
3	LatexIBA 01/2011 - 01/2005
3	AllergensIBA 01/2011 - 01/2005
3	Immunoglobulin G (IgG)IBA 12/2008 - 12/2003
2	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 01/2021 - 11/2019
2	SaltsIBA 01/2021 - 11/2019
2	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 01/2013
2	Phosphotransferases (Kinase)IBA 10/2020 - 11/2019
2	Calmodulin (Calcium-Dependent Activator Protein)IBA 10/2020 - 01/2020
2	Fluorine-18IBA 07/2020 - 01/2020
2	KN 93IBA 01/2020 - 02/2006
2	GraphiteIBA 01/2020 - 11/2016
2	Membrane LipidsIBA 01/2020 - 01/2013
2	DysferlinIBA 01/2020 - 01/2017
2	Protein Isoforms (Isoforms)IBA 01/2020 - 01/2008
2	Green Fluorescent ProteinsIBA 11/2019 - 03/2009
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 10/2006
2	empagliflozinIBA 12/2018 - 01/2018
2	EnzymesIBA 10/2018 - 09/2016
2	Therapeutic UsesIBA 01/2017 - 01/2016
2	Fingolimod Hydrochloride (FTY720)FDA Link 04/2015 - 10/2014
2	CaMKII inhibitor AIPIBA 08/2013 - 02/2006
2	Adenosine Triphosphatases (ATPase)IBA 09/2005 - 12/2004
2	Trastuzumab (Herceptin)FDA Link 07/2004 - 12/2003
1	Oxidants (Oxidizing Agents)IBA 02/2022
1	PLX5622IBA 01/2022
1	AminesIBA 01/2022
1	pyrimidineIBA 01/2022
1	acetamideIBA 01/2022
1	Oxygen (Dioxygen)IBA 12/2021
1	Connexin 43 (Connexin43)IBA 12/2021
1	ConnexinsIBA 12/2021

Therapy/Procedure

13	Therapeutics 01/2022 - 03/2002
5	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 10/2021 - 01/2018
4	Immunotherapy 12/2008 - 12/2003
3	Length of Stay 01/2019 - 03/2002
3	Radiotherapy 01/2013 - 01/2005
3	Drug Therapy (Chemotherapy) 01/2013 - 01/2005
2	Micro-Electrical-Mechanical Systems 01/2020 - 01/2018
2	Electrodes (Electrode) 01/2011 - 11/2009